drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular immunotherapy; CAR T cells)
drug_description
Autologous, gene-modified T cells engineered to express chimeric antigen receptors that target CD20 and CD30, enabling antigen-dependent T-cell activation and cytotoxic killing of malignant cells; administered intravenously after lymphodepletion for relapsed/refractory CD20/CD30-positive lymphomas.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express chimeric antigen receptors that bind CD20 and CD30 on malignant lymphocytes, triggering antigen-dependent T-cell activation independent of the native TCR and inducing cytotoxic killing via perforin/granzyme release and cytokine secretion, leading to elimination of CD20+/CD30+ tumor cells.
drug_name
anti-CD20/CD30 CAR-T cells
nct_id_drug_ref
NCT06519344